Literature DB >> 16026747

Heavy chain diseases.

Dietlind L Wahner-Roedler1, Robert A Kyle.   

Abstract

Heavy chain diseases (HCDs) are rare B-cell lymphoplasma-cell proliferative disorders characterized by production of truncated monoclonal immunoglobulin heavy chains without associated light chains. HCDs involving the three main immunoglobulin classes have been described; alpha-HCD is the most common and has the most uniform presentation, gamma- and mu-HCDs have variable clinical presentations and histopathologic features. HCDs can be thought of as variant types of non-Hodgkin lymphoma: alpha-HCD presents as an extranodal marginal-zone lymphoma of mucosa-associated lymph-node tissue, gamma-HCD as lymphoplasmacytoid non-Hodgkin lymphoma, and mu-HCD as small lymphocytic non-Hodgkin lymphoma or chronic lymphocytic leukemia. Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy chain without a bound light chain in the serum or urine. Prognosis is variable, and no standardized effective treatment programs are available except for alpha-HCD, which in its early stage may respond to antibiotics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026747     DOI: 10.1016/j.beha.2005.01.029

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  12 in total

1.  Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases.

Authors:  Shannon Bieliauskas; Raymond R Tubbs; Chris M Bacon; Camellia Eshoa; Kathryn Foucar; Sarah E Gibson; Steven H Kroft; Aliyah R Sohani; Steven H Swerdlow; James R Cook
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma.

Authors:  Fatima Hamadeh; Stephen MacNamara; Chris M Bacon; Aliyah R Sohani; Steven H Swerdlow; James R Cook
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

3.  Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry.

Authors:  Katie L Thoren; Marion Eveillard; Patrick Chan; Sital Doddi; Sun Cho; Kazunori Murata
Journal:  Clin Biochem       Date:  2019-12-26       Impact factor: 3.281

4.  T cell receptor rearrangements in a patient with γ-heavy chain disease: A case report.

Authors:  Hebing Zhou; Wenming Chen; Juan Zhang; Hui Zeng; Yuan Jian; Chenxiao Fu
Journal:  Oncol Lett       Date:  2016-05-04       Impact factor: 2.967

Review 5.  Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update.

Authors:  Roberto Ria; Franco Dammacco; Angelo Vacca
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

6.  Gamma-heavy chain monoclonal gammopathy with undetermined significance (MGUS).

Authors:  Yuriko Zushi; Miho Sasaki; Toshiharu Saitoh; Yumi Aoyama; Yuta Gotoh; Hiroko Tsunemine; Taiichi Kodaka; Atsuo Okamura; Takayuki Takahashi
Journal:  J Clin Exp Hematop       Date:  2019-08-08

7.  Gamma heavy chain disease in a patient with rheumatoid arthritis--a laboratory evaluation.

Authors:  Wibke Johannis; Jenny Blommer; Andreas R Klatt; Joerg H Renno; Klaus Wielckens
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

8.  Gamma heavy-chain disease accompanied with follicular lymphoma: a case report.

Authors:  Paula San-José; Vicente Aguadero; Granada Perea; Meritxell Estrada; Eugenio Berlanga
Journal:  Biochem Med (Zagreb)       Date:  2018-02-15       Impact factor: 2.313

9.  Two Cases of γ-Heavy Chain Disease and a Review of the Literature.

Authors:  I Ramasamy; Z Rudzki
Journal:  Case Rep Hematol       Date:  2018-08-12

10.  Gamma heavy chain disease (γ-HCD) as iatrogenic immunodeficiency- associated lymphoproliferative disorder: Possible emergent subtype of rheumatoid arthritis-associated γ-HCD.

Authors:  Hiroko Tsunemine; Yuriko Zushi; Miho Sasaki; Yuko Nishikawa; Akiyo Tamura; Yumi Aoyama; Taiichi Kodaka; Tomoo Itoh; Takayuki Takahashi
Journal:  J Clin Exp Hematop       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.